Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Eupraxia Pharmaceuticals Inc

Healthcare CA EPRX

10.86CAD
0.21(1.97%)

Last update at 2026-03-10T20:00:00Z

Day Range

10.4811.17
LowHigh

52 Week Range

3.9612.86
LowHigh

Fundamentals

  • Previous Close 10.65
  • Market Cap608.29M
  • Volume35121
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.60333M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -35.26649M -39.18471M -23.91722M -23.36955M -4.01064M
Minority interest 0.24M 0.75M 0.66M 0.38M -0.45389M
Net income -34.93749M -37.39171M -23.25937M -22.98961M -3.99720M
Selling general administrative 15.71M 9.65M 5.53M 8.41M 1.27M
Selling and marketing expenses - 0.14M - - -
Gross profit -0.23525M -0.20991M - - -
Reconciled depreciation 0.17M 0.16M 0.19M 0.11M 0.12M
Ebit -33.95248M -37.60534M -23.20393M -18.19966M -2.24619M
Ebitda -33.71723M -37.39543M -22.13558M -21.96133M -2.01220M
Depreciation and amortization 0.24M 0.21M - - -
Non operating income net other - - - - -
Operating income -36.99363M -36.89674M -23.23561M -20.96741M -2.24619M
Other operating expenses 36.99M 37.92M - - -
Interest expense 1.31M 1.58M 1.59M 1.30M 1.88M
Tax provision 0.00180M 0.04M - - -
Interest income 1.24M 0.86M 0.67M 2.40M 0.00043M
Net interest income 0.56M -0.30720M -1.01904M -1.23096M -1.88121M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00247M -0.08967M - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 36.76M 37.92M 23.20M 18.68M 2.25M
Cost of revenue 0.24M 0.21M - - -
Total other income expense net 1.73M -2.28796M 0.31M -3.46091M 0.12M
Discontinued operations - - - - -
Net income from continuing ops -25.74449M -28.96601M -23.91721M -23.36955M -4.01064M
Net income applicable to common shares -25.50254M -28.22080M -23.25937M -22.98961M -3.99720M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 34.94M 26.72M 25.88M 31.22M 1.45M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.36M - - -
Total liab 3.10M 25.55M 13.02M 10.84M 23.12M
Total stockholder equity 33.40M 2.92M 12.86M 20.39M -21.20976M
Deferred long term liab - - - - -
Other current liab - 11.76M - 0.00501M 6.94M
Common stock - 122.52M 92.34M 80.71M 23.80M
Capital stock 148.07M 92.91M 92.34M 80.71M 23.80M
Retained earnings -131.00383M -139.11401M -97.44614M -74.18676M -51.19716M
Other liab - - - - 0.38M
Good will - - - - -
Other assets - 0.00000M 0.00337M 0.03M -
Cash 33.10M 25.50M 24.74M 20.89M 0.15M
Cash and equivalents - - - - -
Total current liabilities 3.10M 25.55M 4.14M 2.27M 22.54M
Current deferred revenue - - - - -
Net debt - -11.72199M - - 12.37M
Short term debt - 13.78M 0.00000M 0.00000M 17.57M
Short long term debt - 10.40M 0.11M 0.09M 12.52M
Short long term debt total - 13.78M - - 0.20M
Other stockholder equity - 23.09M 17.96M 13.86M -
Property plant equipment - - 0.70M 0.59M 0.32M
Total current assets 34.44M 26.11M 25.18M 30.60M 1.14M
Long term investments - - - - -
Net tangible assets - - 12.86M 20.39M -21.20976M
Short term investments - - 0.00000M 9.01M -
Net receivables - 0.25M 0.12M 0.43M 0.62M
Long term debt - - 10.30M 9.26M -
Inventory - 0.00000M - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -3.56886M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00910M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.51M 0.61M 0.70M 0.62M 0.32M
Capital lease obligations 0.07M 0.05M 0.14M 0.20M 0.25M
Long term debt total - - 10.37M 9.40M 0.20M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.07516M -0.07338M 9.01M -9.00000M -9.00000M
Change to liabilities - - 1.78M -0.46748M 0.85M
Total cashflows from investing activities -0.07516M -0.09903M 8.70M -14.44982M 0.02M
Net borrowings -9.13746M -0.07944M -0.18518M 12.08M -0.39070M
Total cash from financing activities 45.78M 27.84M 13.52M 49.92M -0.62664M
Change to operating activities - - -0.02053M 0.07M 0.00291M
Net income -25.74449M -37.39171M -23.25937M -22.98961M -3.99720M
Change in cash 13.76M 1.08M 3.84M 20.74M -1.00595M
Begin period cash flow 19.34M 18.26M 20.89M 0.15M 1.16M
End period cash flow 33.10M 19.34M 24.74M 20.89M 0.15M
Total cash from operating activities -29.99449M -27.91642M -18.77643M -14.64163M -0.40378M
Issuance of capital stock 54.56M 15.89M 13.30M 37.83M -
Depreciation 0.24M 0.16M 0.19M 0.11M 0.12M
Other cashflows from investing activities 0.03M -0.00181M 9.01M -5.01815M -0.05669M
Dividends paid - - - - -
Change to inventory - -0.57791M - - -
Change to account receivables -0.10139M -0.13998M 0.31M 0.19M 0.73M
Sale purchase of stock 54.92M 21.16M 13.71M 37.83M -
Other cashflows from financing activities 0.36M 12.10M - 0.00000M -0.23595M
Change to netincome - - 2.22M 8.45M 1.89M
Capital expenditures 0.10M 0.07M 0.31M 0.43M 0.43M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -6.76469M 6.33M 2.07M -0.17626M 1.56M
Stock based compensation 3.22M 1.41M 2.02M 4.21M 0.23M
Other non cash items -0.94403M 1.58M 1.16M 3.41M 1.69M
Free cash flow -30.09872M -28.01545M -19.08480M -15.07330M -0.40393M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 0.21 1.97% 10.86 - - - 7.79 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -0.48 4.64% 9.87 - 11.59 9.31 57.98 6.52 20.27
MSCL
Satellos Bioscience Inc.		 -2.98 18.90% 12.79 4.81 - - 5.61 6.47
HBP
Helix BioPharma Corp.		 0.10 5.41% 1.95 - - - 8.70 -6.3589
MDNA
Medicenna Therapeutics Corp		 0.02 2.33% 0.88 - 204.08 - 7.00 -6.1093

Reports Covered

Stock Research & News

View All

Profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4

Key Executives

Name Title Year Born
Dr. James A. Helliwell FRCPC, M.D. CEO & Director 1974
Mr. Bruce G. Cousins CPA, C.A., CPA Pres & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Bus. Officer NA
Mr. Bruce G. Cousins C.A., CPA President & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer & COO 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Business Officer NA
Dr. Mark M. Kowalski M.D., Ph.D. Chief Medical Officer 1955
Dr. Rahul Sarugaser M.B.A., Ph.D. Executive Vice President of Corporate Development NA
Mr. Alexander John Rothwell Eng., M.B.A. Chief Financial Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.